Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $19.63 Consensus PT from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $19.6250.

A number of equities analysts have issued reports on BCYC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Jefferies Financial Group raised Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. Finally, Truist Financial assumed coverage on Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price on the stock.

Bicycle Therapeutics Price Performance

NASDAQ:BCYC opened at $4.78 on Wednesday. Bicycle Therapeutics has a one year low of $4.77 and a one year high of $10.32. The company has a market cap of $331.59 million, a PE ratio of -1.32 and a beta of 1.65. The firm has a 50-day moving average of $5.97 and a 200-day moving average of $6.84.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares in the company, valued at $3,998,714.16. This represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. The trade was a 4.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 38,029 shares of company stock valued at $251,966 over the last three months. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. Assetmark Inc. lifted its position in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after buying an additional 1,552 shares in the last quarter. Man Group plc grew its holdings in shares of Bicycle Therapeutics by 4.8% in the fourth quarter. Man Group plc now owns 42,860 shares of the company’s stock valued at $303,000 after acquiring an additional 1,969 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Bicycle Therapeutics by 1.6% during the second quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after acquiring an additional 2,243 shares during the last quarter. Virtus Investment Advisers LLC increased its position in shares of Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after acquiring an additional 2,659 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in Bicycle Therapeutics by 21.7% during the third quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after acquiring an additional 2,668 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.